Market Movers collected the best responses from investors and analysts on Eli Lilly. A large-scale study has reported that the pharmaceutical company’s experimental Alzheimer’s drug has slowed the progression of the disease. The stock hit a new all-time high in Wednesday’s session. Lilly closed the day up 6.6%. If the drug, called donamab, is given the green light for public use by the Food and Drug Administration, it could be the start of a big run for stocks, experts said. The drugmaker said it plans to seek FDA approval as soon as this quarter. Eli Lilly is currently held in Jim Cramer’s philanthropic portfolio.
[ad_2]
Comments